Alimera Sciences (STU:ASZ1) Net Change in Cash : €0.96 Mil (TTM As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Alimera Sciences Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Alimera Sciences's Net Change in Cash for the three months ended in Mar. 2024 was €2.08 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 was €0.96 Mil.

Alimera Sciences Net Change in Cash Historical Data

The historical data trend for Alimera Sciences's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alimera Sciences Net Change in Cash Chart

Alimera Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Change in Cash

Get a 7-Day Free Trial

-3.26

1.47

4.69

-10.61

6.22

Alimera Sciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Change in Cash	Get a 7-Day Free Trial															7.30	5.25	-9.83	3.46	2.08

Alimera Sciences Net Change in Cash Calculation

Alimera Sciences's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-13.077	+	-69.263	+	88.49	+	0.073
	=	6.22

Alimera Sciences's Net Change in Cash for the quarter that ended in Mar. 2024

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -0.521 + -0.019 + 2.73 + -0.114

= 2.08

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.96 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alimera Sciences Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Alimera Sciences's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Alimera Sciences (STU:ASZ1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alimera Sciences Inc (STU:ASZ1) » Definitions » Net Change in Cash

Comparable Companies

ZOM LFCR TKNO OPTN ELTP RGC AQST EBS ESPR ETON ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 XSWX:SDZ VTRS NBIX

Traded in Other Exchanges

ALIM:USA ASZ1:Germany

Address

6310 Town Square, Suite 400, Alpharetta, GA, USA, 30005

Website

https://www.alimerasciences.com

Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a leading cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East.

Alimera Sciences (STU:ASZ1) Headlines

No Headlines